Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

PLX5622 hemifumarate

PLX5622 hemifumarate
PLX5622 hemifumarate is a highly selective, brain-penetrant, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and Ki of 5.9 nM. It allows for extended and specific microglial elimination preceding and during pathology development and demonstrates desirable PK properties in various animals [1] [2].
Catalog No. T12505

Resource Download

PLX5622 hemifumarate

Catalog No. T12505

PLX5622 hemifumarate is a highly selective, brain-penetrant, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and Ki of 5.9 nM. It allows for extended and specific microglial elimination preceding and during pathology development and demonstrates desirable PK properties in various animals [1] [2].
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
200 mg$1,1681-2 weeks
Bulk & Custom
Add to Cart
Questions
View More

Product Introduction

Bioactivity
Description
PLX5622 hemifumarate is a highly selective, brain-penetrant, and orally active CSF1R inhibitor with an IC50 of 0.016 μM and Ki of 5.9 nM. It allows for extended and specific microglial elimination preceding and during pathology development and demonstrates desirable PK properties in various animals [1] [2].
In vitro
PLX5622 hemifumarate (1-20 μM; 3 days) effectively depletes microglia without affecting oligodendrocytes or astrocytes in cerebellar slices. At 4 μM for 3 days, it reduces NG2+ or PDGFRα+ cells by 30-40%, increasing to 90-95% at 20 μM. No reduction in NG2+ or PDGFRα+ OPCs is observed at 1 μM or 2 μM PLX5622 despite robust (~95%) depletion of microglial cells [3].
In vivo
In preclinical studies, PLX5622 hemifumarate demonstrates significant microglial depletion in adult C57/Bl6 wild-type mice when administered at 1200 ppm in chow for durations of 3 days to 3 weeks, resulting in approximately 80% reduction after 3 days, and a 99% reduction after 3 weeks. Similar outcomes were observed in different brain regions including the cortex, striatum, cerebellum, and hippocampus when administered for 3 weeks. Intraperitoneal injections of 50 mg/kg in neonatal and adult rats for 14 days resulted in 80-90% microglia depletion within the first 3 days, surpassing 90% by day 7, and achieving more than 96% depletion by day 14, while astrocyte levels remained unchanged. Notably, neonates required only a single daily injection, while adults needed twice-daily injections for effective depletion. Furthermore, administration of PLX5622 in AIN-76A chow at 1200 mg/kg for 28 days significantly reduced microglia in the CNS of 14-month-old 5xfAD mice. The pharmacokinetic profile of PLX5622 across various species revealed differences in bioavailability, clearance, and half-life, notably demonstrating efficient absorption and clearance rates. For gavage dosing preparations, PLX5622 hemifumarate is dissolved in DMSO, mixed with a diluent consisting of hydroxypropyl methyl cellulose and Polysorbate 80, and sonicated to achieve a uniform suspension for administration.
Chemical Properties
Molecular Weight453.45
FormulaC25H23F2N5O5
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 100 mg/mL (220.53 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.2053 mL11.0266 mL22.0531 mL110.2657 mL
5 mM0.4411 mL2.2053 mL4.4106 mL22.0531 mL
10 mM0.2205 mL1.1027 mL2.2053 mL11.0266 mL
20 mM0.1103 mL0.5513 mL1.1027 mL5.5133 mL
50 mM0.0441 mL0.2205 mL0.4411 mL2.2053 mL
100 mM0.0221 mL0.1103 mL0.2205 mL1.1027 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy PLX5622 hemifumarate | purchase PLX5622 hemifumarate | PLX5622 hemifumarate cost | order PLX5622 hemifumarate | PLX5622 hemifumarate chemical structure | PLX5622 hemifumarate in vivo | PLX5622 hemifumarate in vitro | PLX5622 hemifumarate formula | PLX5622 hemifumarate molecular weight